Join
Live feed
·
PRReleasevia Quantisnow
Aldeyra Therapeutics Inc. logo

Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa

ByQuantisnow·Wall Street's wire, on your screen.
ALDX· Aldeyra Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALDX (Aldeyra Therapeutics Inc.) and more on Quantisnow.